Natera, Inc.
NTRA
$6.37 (2.84%)
1D
1W
3M
1Y
5Y
ALL
Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Seeking Alpha • 5 days ago • NTRA
Natera, Inc. (NTRA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Zacks Investment Research • 9 days ago • NTRA
NTRA & CytoDyn Partner to Advance ctDNA-Guided Development in mCRC
Zacks Investment Research • 16 days ago • NTRA
NTRA & Diakonos Partner to Use Signatera in Refractory Melanoma Trial
24/7 Wall Street • 19 days ago • NTRA
Why Natera Is My Favorite Stock Idea for the Rest of 2026
Business Wire • 20 days ago • NTRA
Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.